Boulware, David
Moffitt Cancer Center
10 papers on CoChat
Most cited papers
- Verified
A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis After Chemoradiation
Eschrich, S. A., Pramana, J., Zhang, H., Zhao, H., Boulware, D., Lee, J.-H., Bloom, G., Rocha-Lima, C., Kelley, S., Calvin, D. P., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics
Breast Cancer Treatment StudiesRadiation Therapy and Dosimetry
Cited by 360
- Verified
Fall in C-Peptide During First 2 Years From Diagnosis
Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes
Diabetes and associated disordersDiabetes Management and Research
Cited by 319
- Verified
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
Bewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., & Hazlehurst, L. A. (2008) · Molecular Cancer Therapeutics
Chronic Myeloid Leukemia TreatmentsProtein Tyrosine Phosphatases
Cited by 150
- Verified
The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening
Jacobsen, L. M., Bocchino, L., Evans-Molina, C., DiMeglio, L., Goland, R., Wilson, D. M., Atkinson, M. A., Aye, T., Russell, W. E., Wentworth, J. M., et al. (2020) · Diabetologia
Diabetes and associated disordersDiabetes Management and Research
Cited by 133
- Verified
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients
Sosenko, J. M., Skyler, J. S., Palmer, J. P., Krischer, J. P., Yu, L., Mahon, J., Beam, C. A., Boulware, D. C., Rafkin, L., Schatz, D., et al. (2013) · Diabetes Care
Diabetes and associated disordersDiabetes Management and Research
Cited by 123
- Verified
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies
Yu, L., Boulware, D. C., Beam, C. A., Hutton, J. C., Wenzlau, J. M., Greenbaum, C. J., Bingley, P. J., Krischer, J. P., Sosenko, J. M., Skyler, J. S., et al. (2012) · Diabetes Care
Diabetes and associated disordersDiabetes Management and Research
Cited by 104
- Verified
A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history
Sosenko, J. M., Skyler, J. S., DiMeglio, L. A., Beam, C. A., Krischer, J. P., Greenbaum, C. J., Boulware, D., Rafkin, L. E., Matheson, D., Herold, K. C., et al. (2015) · Diabetes Care
Diabetes and associated disordersDiabetes Management and Research
Cited by 86
- Verified
HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression
Pugliese, A., Boulware, D., Yu, L., Babu, S., Steck, A. K., Becker, D., Rodriguez, H., DiMeglio, L., Evans-Molina, C., Harrison, L. C., et al. (2016) · Diabetes
Diabetes and associated disordersGenetic Associations and Epidemiology
Cited by 68
- Verified
Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms.
Tafreshi, N. K., Pandya, D. N., Tichacek, C. J., Budzevich, M. M., Wang, Z., Reff, J. N., Engelman, R. W., Boulware, D. C., Chiappori, A. A., Strosberg, J. R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging
Radiopharmaceutical Chemistry and ApplicationsNeuroendocrine Tumor Research Advances
Cited by 50
- Verified
The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
Sosenko, J. M., Skyler, J. S., Mahon, J., Krischer, J. P., Beam, C. A., Boulware, D. C., Greenbaum, C. J., Rafkin, L. E., Cowie, C., Cuthbertson, D., et al. (2012) · Diabetes Care
Diabetes and associated disordersDiabetes Management and Research
Cited by 44
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free